|Bid||18.81 x 900|
|Ask||22.61 x 1100|
|Day's Range||22.29 - 23.35|
|52 Week Range||15.80 - 26.57|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||26.61|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
Subscribe to Yahoo Finance Plus to view Fair Value for EVOLearn more
CAMBRIDGE, Mass. & HAMBURG, Germany, November 18, 2021--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx’s pipeline expansion efforts
The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.
* STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH * CO-OWNED PIPELINE GAINING MOMENTUM * J.POD (R) REDMOND (US) OPERATIONAL * SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) * GUIDANCE FOR FULL-YEAR 2021 CONFIRMED * WEBCAST AND CONFERENCE CALL TODAY AT 02.